Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3974-3985

  Patnaik, Amita ^a   Rowinsky, Eric K ^a   Tammara, Brinda K ^a   Hidalgo, Manuel ^a   Drengler, Ronald L ^a   Garner, Allison M ^a   Siu, Lillian L ^a   Hammond, Lisa A ^a   Felton, Sally A ^a   Mallikaarjun, Suresh ^a   Von Hoff, Daniel D ^a   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; PIPERANOMETOZINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0034548857     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3974     Document Type: Article

References (29)

1. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure
2. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in human salivary gland cancer cell
3. Effects of vesnarinone on morbidity and mortality in patients with heart failure
4. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
5. Induction of differentiation and apoptosis, and Le(y) antigen expression by treatment with vesnarinone in a human salivary cancer cell line
6. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) on the growth of gastric cancer cell lines
7. Characteristics of antitumor activity of vesnarinone against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice
8. Vesnarinone as anti-tumor agent with differentiation or apoptosis inducing activity in human cancer xenografts in nude mice
9. Induction of cyclin-dependent kinase inhibitor, p21(WAF1), by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxymenzoyl-1-peperazinyl]-2(1H)-quinolone (vesnarinone) in a human salivary cancer cell line with mutant p53 gene
10. Metabolism of vesnarinone by activated neutrophils: Implications for vesnarinone-induced agranulocytosis
11. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure
12. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line
13. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis
14. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines
15. Antiproliferative activity of vesnarinone in 64 human tumor cell lines of various histogenesis
16. Vesnarinone inhibits nucleoside and nucleobase transport
17. Le(y) antigen expression is correlated with apoptosis (programmed cell death)
18. Pharmacokinetic profile of OPC-8212 in humans: A new, nonglycosidic, inotropic agent
19. Effect of CYP3A inhibition on vesnarinone metabolism
20. High-performance liquid chromatographic procedure for the determination of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone, in human plasma and urine
21. Gemcitabine in advanced breast cancer
22. Advanced breast cancer: A phase II trial with gemcitabine
23. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer
24. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
25. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer
26. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced nonsmall cell lung cancer
27. Single-agent gemcitabine in non-small cell lung cancer: The French experience
28. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine